医学分子生物学杂志
醫學分子生物學雜誌
의학분자생물학잡지
FOREIGN MEDICAL SCIENCES
2014年
6期
347-349
,共3页
老年人%脓毒血症%细胞免疫功能%胸腺肽
老年人%膿毒血癥%細胞免疫功能%胸腺肽
노년인%농독혈증%세포면역공능%흉선태
elderly%sepsis%cellular immune function%thymosin
目的：探讨老年脓毒血症患者细胞免疫功能的变化,观察胸腺肽 a1的治疗效果。方法120例老年脓毒症患者随机分为两组：干预组和对照组,每组60例。对照组给予常规治疗,干预组在常规治疗基础上加用胸腺肽 a11.6 mg/ d,皮下注射,疗程1周。比较两组患者治疗前后细胞免疫功能﹑ APACHEⅡ评分和住院死亡率。结果两组患者治疗前 CD4+﹑ CD8+﹑ CD4+/ CD8+﹑ APACHE Ⅱ评分差异无统计学意义(P ﹥0.05)。治疗后干预组 CD4+﹑ CD4+/ CD8+较常规治疗组明显增高(P ﹤0.001), CD8+明显降低(P﹤0.001), APACHEⅡ评分和住院死亡率亦明显降低(P ﹤0.05)。结论老年脓毒血症患者细胞免疫功能明显降低,胸腺肽 a1能改善此类患者的细胞免疫功能,提高临床治疗效果。
目的：探討老年膿毒血癥患者細胞免疫功能的變化,觀察胸腺肽 a1的治療效果。方法120例老年膿毒癥患者隨機分為兩組：榦預組和對照組,每組60例。對照組給予常規治療,榦預組在常規治療基礎上加用胸腺肽 a11.6 mg/ d,皮下註射,療程1週。比較兩組患者治療前後細胞免疫功能﹑ APACHEⅡ評分和住院死亡率。結果兩組患者治療前 CD4+﹑ CD8+﹑ CD4+/ CD8+﹑ APACHE Ⅱ評分差異無統計學意義(P ﹥0.05)。治療後榦預組 CD4+﹑ CD4+/ CD8+較常規治療組明顯增高(P ﹤0.001), CD8+明顯降低(P﹤0.001), APACHEⅡ評分和住院死亡率亦明顯降低(P ﹤0.05)。結論老年膿毒血癥患者細胞免疫功能明顯降低,胸腺肽 a1能改善此類患者的細胞免疫功能,提高臨床治療效果。
목적：탐토노년농독혈증환자세포면역공능적변화,관찰흉선태 a1적치료효과。방법120례노년농독증환자수궤분위량조：간예조화대조조,매조60례。대조조급여상규치료,간예조재상규치료기출상가용흉선태 a11.6 mg/ d,피하주사,료정1주。비교량조환자치료전후세포면역공능﹑ APACHEⅡ평분화주원사망솔。결과량조환자치료전 CD4+﹑ CD8+﹑ CD4+/ CD8+﹑ APACHE Ⅱ평분차이무통계학의의(P ﹥0.05)。치료후간예조 CD4+﹑ CD4+/ CD8+교상규치료조명현증고(P ﹤0.001), CD8+명현강저(P﹤0.001), APACHEⅡ평분화주원사망솔역명현강저(P ﹤0.05)。결론노년농독혈증환자세포면역공능명현강저,흉선태 a1능개선차류환자적세포면역공능,제고림상치료효과。
Objective To investigate the changes of cellular immune function in elderly pa-tients with sepsis, and observe the therapeutic effect of thymosin alpha 1. Methods A total of 120 elderly patients with sepsis were randomly divided into two groups: intervention group and control group (60 in each group) . Conventional therapy was adopted in the control group. Thymosin alpha 1 at 1 1. 6mg/ d was subcutaneously given to patients for 1 weeks in the intervention group based on the conventional therapy. The cellular immune function before and after treatment, APACHE Ⅱscore and in-hospital mortality were compared between the two groups. Results There were no sig-nificant differences between two groups in CD4 + , CD8 + , CD4 / CD8 + , and APACHE Ⅱ score be-fore treatment (P ﹥ 0. 05) . After treatment, CD4 + and CD4 + / CD8 + were significantly increased (P ﹤ 0. 001), but CD8 + decreased obviously in the intervention group as compared with control group (P ﹤ 0. 001). APACHE Ⅱ score and in-hospital mortality were lower in the intervention group than in the control group (P ﹤ 0. 05) . Conclusion The cellular immune function of elderly patients with sepsis is impaired significantly. Thymosin alpha 1 can profoundly improve the clinical therapeutic outcomes of such patients by increasing their cellular immune function.
